--- title: Buy Invokana (Canagliflozin) 100mg Pills Online description: Invokana (Canagliflozin) 100mg is a trusted medication for type 2 diabetes management. Order from our secure online pharmacy for reliable delivery. type: product language: en url: https://medsforsale.net/buy-invokana-online-en availability: in_stock price_min: 164.99 price_max: 412.99 currency: USD offers: - name: 100mg x 30 pills price: 164.99 - name: 100mg x 60 pills price: 301.99 - name: 100mg x 90 pills price: 412.99 --- # Buy Invokana (Canagliflozin) 100mg Pills Online Invokana, which contains the active ingredient Canagliflozin, is a prominent SGLT2 inhibitor developed by Janssen Pharmaceuticals. It is used to lower blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events. It is an excellent option for patients seeking to manage their glucose levels while protecting heart and kidney health. Our pharmacy offers Invokana in 100mg pills with professional and reliable service. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **100mg** | 30 pills | **$164.99** | $5.50 | In Stock | | **100mg** | 60 pills | **$301.99** | $5.03 | In Stock | | **100mg** | 90 pills | **$412.99** | $4.59 | In Stock | [Buy Now](https://medsforsale.net/buy-invokana-online-en) ## Introduction Invokana (generic name: canagliflozin) is an oral medication approved for the management of type 2 diabetes mellitus in adults. It belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, which facilitates urinary glucose excretion to lower blood sugar levels. Manufactured by Janssen Pharmaceuticals, Invokana is supplied as a 100 mg tablet. In addition to its primary indication for glycemic control, regulatory agencies have approved Invokana for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with established cardiovascular disease. The drug is also investigated for renal protection, although use for chronic kidney disease remains off-label. ## What is Invokana? Invokana is a branded formulation of the active compound canagliflozin. Developed by Janssen Pharmaceuticals and first approved by the U.S. Food and Drug Administration (FDA) in 2013, it is part of the SGLT2 inhibitor drug group that also includes agents such as dapagliflozin and empagliflozin. Each tablet contains 100 mg of canagliflozin, an amount shown in clinical trials to provide effective glucose lowering with an acceptable safety profile. Invokana is taken orally once daily, with or without food, and is intended for adult patients who require additional glycemic control beyond diet, exercise, and first-line oral agents. ## How Invokana Works Canagliflozin selectively blocks the SGLT2 protein located in the proximal tubules of the kidneys. Under normal conditions, SGLT2 reabsorbs ~90 % of filtered glucose back into the bloodstream. By inhibiting this transporter, Invokana reduces glucose reabsorption, leading to increased urinary glucose excretion (approximately 60-80 g per day). The resulting caloric loss contributes to modest weight reduction, while the osmotic diuresis promotes a mild decrease in blood pressure. Onset of glucose-lowering effect occurs within 24 hours of the first dose, and steady-state pharmacokinetics are reached after 4-5 days. Canagliflozin is primarily eliminated unchanged via the kidneys; renal impairment markedly reduces its efficacy and influences dosing recommendations. ## Conditions Treated with Invokana - **Type 2 Diabetes Mellitus (T2DM)** - Invokana improves glycated hemoglobin (HbA1c) by 0.5-1.0 % when added to metformin or other oral agents, fulfilling FDA and European Medicines Agency (EMA) criteria for glycemic control. - **Cardiovascular Risk Reduction** - In the CANVAS Program (multicenter, randomized trial), canagliflozin lowered the composite outcome of cardiovascular death, myocardial infarction, or stroke by 14 % compared with placebo, leading to its approval for cardiovascular risk mitigation. - **Heart Failure (HF) with Reduced Ejection Fraction** - Post-marketing analyses and the CREDENCE trial demonstrated a 22 % relative risk reduction for hospitalization due to heart failure, supporting its use in patients with established HF. These indications are based on robust phase III data and have been incorporated into international diabetes and cardiology guidelines. ## Off-Label and Investigational Uses of Invokana - **Chronic Kidney Disease (CKD) without Diabetes** - Small-scale studies suggest canagliflozin may slow estimated glomerular filtration rate (eGFR) decline in non-diabetic CKD, but regulatory approval for this indication is pending. - **Non-Alcoholic Fatty Liver Disease (NAFLD)** - Early phase II trials have reported improvements in hepatic steatosis markers; however, long-term outcomes remain unproven. - **Weight Management in Obesity** - Because of its caloric loss, canagliflozin is occasionally explored as an adjunct in obesity management, yet data are insufficient for formal recommendation. These off-label applications are not approved by the FDA or EMA. Patients should discuss any consideration of such uses exclusively with a qualified healthcare professional, ensuring that benefits and risks are carefully evaluated. ## Is Invokana the Right Medication for You? Invokana is suitable for adults with type 2 diabetes who have an eGFR ≥ 30 mL/min/1.73 m² and require additional glycemic control despite optimized lifestyle measures and metformin therapy. It is also indicated for those with established atherosclerotic cardiovascular disease or heart failure who can benefit from its cardioprotective effects. Contraindications include: - Severe renal impairment (eGFR < 30 mL/min/1.73 m²) - Active bladder cancer - Pregnancy or lactation (insufficient safety data) - Prior hypersensitivity to canagliflozin or any tablet excipients Patients with a history of recurrent genital mycotic infections, hypotension, or on high-dose loop diuretics should be evaluated carefully, as the drug may exacerbate these conditions. ## Risks, Side Effects, and Interactions ### Common - Genital mycotic infections (e.g., candidiasis) - up to 5 % in women, 2 % in men - Urinary tract infections (UTIs) - mild dysuria or frequency - Increased urination (polyuria) due to osmotic diuresis - Mild elevation of low-density lipoprotein (LDL) cholesterol ### Rare - Volume depletion leading to dizziness, especially in patients on diuretics or with low baseline blood pressure - Acute kidney injury (AKI) - reversible upon drug discontinuation and rehydration - Bone fracture - observed more frequently in long-term studies, possibly related to decreased vitamin D activation ### Serious - **Diabetic ketoacidosis (DKA)** - Euglycemic DKA can occur with normal or mildly elevated blood glucose; prompt recognition and emergency care are essential. - **Severe genital infections** - Necrotizing fasciitis of the perineum (Fournier’s gangrene), though rare (<1 per 10,000 patient-years), requires immediate surgical intervention. - **Amputation risk** - The CANVAS trial identified an increased incidence of lower-extremity amputations, predominantly at the toe or metatarsal level. #### Drug-Drug Interactions - **Renin-angiotensin-aldosterone system (RAAS) inhibitors** - May accentuate hypotensive effects; monitor blood pressure. - **Loop or thiazide diuretics** - Combined use can heighten volume depletion; adjust diuretic dose if needed. - **Insulin or insulin secretagogues (e.g., sulfonylureas)** - Additive glucose-lowering may raise hypoglycemia risk; dose reductions may be warranted. #### Drug-Food Interactions - No significant food effect; tablets may be taken with or without meals. - Excessive alcohol can potentiate hypoglycemia when combined with insulin therapy and may increase the risk of ketoacidosis. ## Use: Dosing, Missed Dose, Overdose - **Standard dosing** - The usual starting dose is 100 mg taken once daily. For patients with eGFR ≥ 60 mL/min/1.73 m², dose may be increased to 300 mg once daily if additional glycemic control is needed. - **Renal adjustment** - For eGFR 45-59 mL/min/1.73 m², continue 100 mg; for eGFR 30-44 mL/min/1.73 m², limit to 100 mg and reassess renal function regularly. - **Missed dose** - If a dose is forgotten and it is less than 12 hours until the next scheduled dose, skip the missed tablet and resume the regular schedule. Do not double-dose. - **Overdose** - In the event of ingestion of a larger amount than prescribed, seek immediate medical attention. Symptoms may include severe dehydration, hypotension, or pronounced polyuria. Supportive care with intravenous fluids and monitoring of renal function is the mainstay of treatment. **Practical precautions** - Stay well-hydrated, avoid excessive alcohol, and refrain from operating heavy machinery until the diuretic effect subsides, typically within a few hours after dosing. ## FAQ - **Can I travel internationally with Invokana?** Invokana tablets are legal for personal use in most countries when accompanied by a prescription label. Keep the medication in its original packaging and store it at room temperature, away from direct sunlight. - **Does food affect the absorption of Invokana?** Food does not significantly alter canagliflozin absorption; the tablet can be taken with meals or on an empty stomach. - **What does the Invokana tablet look like?** The 100 mg tablet is typically round, white, and film-coated, imprinted with “JANSEN 100.” Inactive ingredients include lactose, magnesium stearate, and microcrystalline cellulose. - **Is it safe to use Invokana with a low-sodium diet?** Because canagliflozin promotes natriuresis, patients on a very low-sodium regimen should monitor blood pressure and electrolytes, especially if also taking diuretics. - **How does kidney function influence Invokana therapy?** Renal clearance determines the drug’s effectiveness; reduced eGFR diminishes glucose excretion and may necessitate dose reduction or discontinuation. - **Can Inv Kanada cause changes in cholesterol levels?** Clinical trials have shown a modest rise in LDL cholesterol; routine lipid monitoring is advisable, particularly for patients with existing dyslipidemia. - **What should I do if I develop a genital yeast infection while on Inv Kanada?** Prompt antifungal treatment is recommended. Persistent or severe infections should be evaluated by a clinician to rule out underlying issues. - **Is there a risk of hypoglycemia if I take Inv Kanada without other diabetes medicines?** When used as monotherapy, the risk of hypoglycemia is low because the drug’s glucose-lowering effect is insulin-independent. - **How long can I store Inv Kanada at room temperature?** Tablets remain stable for up to 24 months when kept in a dry environment below 30 °C (86 °F). Do not store near heat sources or in humid bathrooms. - **Does smoking affect the efficacy of Inv Kanada?** Smoking does not directly interfere with canagliflozin’s mechanism, but it contributes to cardiovascular risk, which may offset some of the drug’s protective benefits. ## Glossary **SGLT2 Inhibitor** : A class of drugs that block the sodium-glucose cotransporter-2 in the kidneys, preventing glucose reabsorption and increasing its excretion in urine. **eGFR (Estimated Glomerular Filtration Rate)** : A calculation that approximates kidney filtering capacity, expressed in mL/min/1.73 m², used to guide dosing of renally cleared medications. **Euglycemic Diabetic Ketoacidosis** : A rare form of ketoacidosis where blood glucose levels are normal or only mildly elevated, often precipitated by SGLT2 inhibition. **Polyuria** : Excessive urination, commonly seen with agents that increase urinary glucose loss. ## Buying Invokana from [our online pharmacy](https://medsforsale.net/buy-invokana-online-en) Patients who encounter limited availability, high out-of-pocket costs, or privacy concerns can obtain Invokana through [our online pharmacy](https://medsforsale.net/buy-invokana-online-en). We source the medication directly from licensed, audited manufacturers, ensuring that each tablet meets stringent quality standards comparable to the original brand product. Because we operate as a pharmacy broker service, we can offer the generic formulation at prices close to wholesale cost, reducing the financial burden for many adults managing chronic disease. Our fulfillment network provides discreet packaging and reliable delivery options, typically delivering within 7 days via express shipping or about three weeks with standard airmail. All orders are processed in compliance with international pharmacy regulations, and we maintain strict data-protection protocols to safeguard patient information. For individuals facing insurance barriers or geographic restrictions, this service offers a secure, cost-effective pathway to maintain continuous therapy. ## Disclaimer The information presented about Invokana is intended for general educational purposes only and does not replace professional medical advice. Treatment decisions, including any off-label applications, should be made under the direct supervision of a qualified healthcare provider. Readers are assumed to be responsible adults capable of making informed health choices. [our online pharmacy](https://medsforsale.net/buy-invokana-online-en) provides access to Invokana for individuals who may encounter limited availability, insurance constraints, or who are seeking cost-effective generic alternatives. Always discuss any medication changes with your clinician before initiating, adjusting, or discontinuing therapy.